Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
| ▸ | ABL1 | P00519 | 3/20 | 0.67 |
| ▸ | KDR | P35968 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.67 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | SCD | O00767 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | RAF1 | P04049 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mebendazole SCHEMBL3429179 | 0.89 | ABL1 (0.82) | ALDH1A1HTTLMNACYP1A2ABL1 | |
| Mebendazole SCHEMBL29409261 | 0.89 | ABL1 (0.82) | ALDH1A1HTTLMNACYP1A2ABL1 | |
| Mebendazole SCHEMBL15860 | 0.89 | ABL1 (0.82) | ALDH1A1HTTLMNACYP1A2ABL1 | |
| Mebendazole SCHEMBL21051203 | 0.88 | ABL1 (0.80) | ALDH1A1HTTLMNACYP1A2ABL1 | |
| Mebendazole SCHEMBL27690766 | 0.88 | ABL1 (0.80) | ALDH1A1HTTLMNACYP1A2ABL1 | |
| Mebendazole SCHEMBL17262440 | 0.88 | ABL1 (0.80) | ALDH1A1HTTLMNACYP1A2ABL1 | |
| Mebendazole SCHEMBL28186589 | 0.88 | ABL1 (0.80) | ALDH1A1HTTLMNACYP1A2ABL1 | |
| Mebendazole SCHEMBL21051200 | 0.88 | ABL1 (0.80) | ALDH1A1HTTLMNACYP1A2ABL1 | |
| Mebendazole SCHEMBL28588780 | 0.87 | ABL1 (0.78) | ALDH1A1HTTLMNACYP1A2ABL1 | |
| Nocodazole SCHEMBL8186933 | 0.87 | ABL1 (0.68) | ALDH1A1HTTLMNACYP1A2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202840-A1 | Use of Flubendazole and Vinca Alkaloids for Treatment of Hematological Diseases | UNIVERSITY HEALTH NETWORK (CA) | 2012-08-09 | — | — | US | disclosed |
| EP-1363625-A4 | COMBINATIONS OF DRUGS (E.G., A BENZIMIDAZOLE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS | COMBINATORX INC (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20040063769-A1 | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | COMBINATORX, INC. | 2004-04-01 | — | — | US | disclosed |
| US-6693125-B2 | ADMINISTERING THE DRUGS PENTAMIDINE, AND ONE OF ALBENDAZOLE, MEBENDAZOLE, OR OXIBENDAZOLE; SYNERGISTIC | COMBINATORX INCORPORATED | 2004-02-17 | — | — | US | disclosed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1363625-A1 | COMBINATIONS OF DRUGS (E.G., A BENZIMIDAZOLE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS | Combinatorx, Incorporated (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020165261-A1 | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | ZALICUS INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002058697-A1 | COMBINATIONS OF DRUGS (E.G., A BENZIMIDAZOLE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165261-A1 | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | DHFR, DPYD, VHL | ALDH1A1 346/4885HTT 1884/4885LMNA 2776/4885 |
| US-20120202840-A1 | Use of Flubendazole and Vinca Alkaloids for Treatment of Hematological Diseases | MCL1, BCL9, KIT | ALDH1A1 610/4885HTT 750/4885LMNA 2968/4885 |
| US-20040063769-A1 | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | DHFR, DPYD, VHL | ALDH1A1 346/4885HTT 1884/4885LMNA 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.